English  |  正體中文  |  简体中文  |  2815035  
???header.visitor??? :  27368009    ???header.onlineuser??? :  684
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"melo cruz f"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-2 of 2  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2020-05-25T06:51:44Z Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis Bardia A;Campos-Gomez S;Hurvitz S.A;Yen-Shen Lu;Im S.-A;Franke F;Chow L;Wheatley-Price P;Melo Cruz F;Alam J;Kong O;Diaz-Padilla I;Miller M;Tripathy D.; Bardia A; Campos-Gomez S; Hurvitz S.A; YEN-SHEN LU; Im S.-A; Franke F; Chow L; Wheatley-Price P; Melo Cruz F; Alam J; Kong O; Diaz-Padilla I; Miller M; Tripathy D.
臺大學術典藏 2020-05-25T06:51:44Z Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis Bardia A;Campos-Gomez S;Hurvitz S.A;Yen-Shen Lu;Im S.-A;Franke F;Chow L;Wheatley-Price P;Melo Cruz F;Alam J;Kong O;Diaz-Padilla I;Miller M;Tripathy D.; Bardia A; Campos-Gomez S; Hurvitz S.A; YEN-SHEN LU; Im S.-A; Franke F; Chow L; Wheatley-Price P; Melo Cruz F; Alam J; Kong O; Diaz-Padilla I; Miller M; Tripathy D.

Showing items 1-2 of 2  (1 Page(s) Totally)
1 
View [10|25|50] records per page